




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、CP887679- 0 *Dr. Jaffe is a consultant and receives research support from Roche, Dade Behring and Beckmann Coulter. He has been or presently is a consultant to Ortho Diagnostics, Sensera, Diadexus, Abbott, Hawaii Biotech and Tartagen.CP1051812-10.00.51.00306090 120 150 1800.00.51.00306090 120 150 18
2、00.00.51.00306090 120 150 1800.00.51.00306090 120 150 1800.00.51.00306090 120 150 180CP887679- 2CP956024-120102030060120180240300360CP887679- 3100CP887679- 4Circulation. 1997;95:2053-2059 CP887679- 50.20.11 51050CP887679- 60.20.11 51050CP887679- 7CP886232- 783117414813450671.01.83.53.96.27.8Risk rat
3、io-0.5-6.71.2-10.61.3-11.71.7-22.32.6-23.095% CI CP887679- 8CP1099500-8JACC 41:376, 20036-modeath/MI raten=262ST-depressionP=0.20n=125n=259n=174n=57n=82P=0.13P=0.15TroponinTroponin+CP887679- 9CP1142356-17James et al: Am J Med 115:181, 2003141210864200.01 g/LFRISC-IIDeath and MI at 30 days (%)0.03 g/
4、LP=0.04Below cutoffAbove cutoff0.1 g/LP=0.01P=0.15Cutoff0.01 g/LGUSTO-IV0.03 g/LP0.0010.1 g/LP0.001P0.001Cutoff118017743061665211114762013862658093287464306441,992 5,1232,563 4,5523,446 3,679CP887679- 100.010.020.030.040.050.060.0ABCDEGHTotal CV, %ACS180CentaurImmuno 1AccessAccess2VidasLiaisonRXL CS
5、OpusImmuliteAlpha DxECiAIA 21IFCC Precision Study(Clinical Chem 2004)CP887679- 11OR 4.55; 2.66-7.78Rapid Troponin I AssayCP1148152-9Int J Cardiol 93:113, 2004%NegDeathMIDeath or MI569892130132205Troponin T (0.1 g/L)Troponin T (0.01 g/L)OR 1.80; 1.30-2.541.82; 1.38-2.401.64; 1.31-2.06OR 3.20; 2.22-4.
6、592.26; 1.79-2.851.47; 1.12-1.933.42; 2.57-5.984.29; 3.02-6.09Pos%4115113139862513619711636221301CP887679- 12Assay Positive WBDSA Negative WBDSA TotalBeckman 10% CV+ 17 20 37- 11 106 117Roche 10% CV+ 16 8 24- 12 118 130Beckman 99th%+ 20 38 58- 8 88 96Roche 99th% + 21 44 65- 7 82 89CP887679- 13CP1131
7、968-3NEJM 349:1600, 2003Odds ratioOdds ratioRevascularizationMyeloperoxidase quartile 2Myeloperoxidase quartile 3Myeloperoxidase quartile 4Major adverse cardiac eventsMyeloperoxidase quartile 2Myeloperoxidase quartile 3Myeloperoxidase quartile 430 Days6 MonthsUnadjustedAdjustedCP887679- 14CP1132618-
8、7CP887679- 15CP1104508-19CP887679- 16AHJ 148:577, 2004TnI (0.1 g/L)CK-MB (3.5 g/L)Myo (98/56 g/L)CP1176222-20 min30 min60 min90 minSensitivity2 hr3 hr6 hr6 hrSpecificity TnI (0.4 g/L)TnI (0.1 g/L)TnI (0.07 g/L)CP887679- 17CP1179389-5TnT (0.01)Prog Cardiovasc Dis 47(3), 2004P0.01)P=0.02Thrombus (%)P=
9、0.03TFG 0/1 (%)P0.001TMPG 0/1 (%)CP887679- 18CP956024-13CP887679- 19CP1008642-5CP887679- 20CP1036852-9Conservative InvasiveNo.treatmenttreatmentPrimary endpoint0.1 ng/mL734 4.36.60.1 - 0.418116.54.40.4 - 1.521317.65.4 1.569315.68.8Death or MI0.1 ng/mL734 1.93.00.1 - 0.418112.14.40.4 - 98.6 98.677.0-
10、98.577.0-98.558.4-76.958.4-76.94.7-58.34.7-58.3Death or MI %Death or MI %25252020151510105 50 025252020151510105 50 0CP887679- 22CP1019654-1Pt with event (%)PatientsCharacteristic(no.)Placebo ClopidogrelOverall12,56211.4 9.3Associated MI 3,28313.711.3No associated MI 9,27910.6 8.6Male 7,72611.9 9.1F
11、emale 4,83610.7 9.5 65 yr old 6,354 7.6 5.465 yr old 6,20815.313.3ST-segment deviation 6,27514.311.5No ST-segment deviation 6,287 8.6 7.0Enzymes elevated at entry 3,17613.010.7Enzymes not elevated at entry 9,38610.9 8.8Diabetes 2,84016.714.2No diabetes 9,722 9.9 7.9Low risk 4,187 6.7 5.1Intermediate
12、 risk 4,185 9.4 6.5High risk 4,18418.016.3History of revascularization 2,24614.4 8.4No history of revascularization10,31610.7 9.5Revascularization after randomization 4,57713.911.5No revascularization after randomization 7,98510.0 8.1Relative risk (95% CI)ClopidogrelbetterPlacebobetterCP887679- 23CP
13、1189452-44 peptides related with each other regarding biochemistry and physiological functionAtrial natriureticpeptide (ANP)Brain (or B type)natriuretic peptide(BNP)C-type natriuretic peptide(CNP)Urodilatin, a slightly extended form of ANPCFCDRISGLCCCP887679- 24Common 17-amino acidring structureRing
14、 structure highlyconserved11/17 amino acidsare homologousRing structure essentialfor physiological activityCFCDRISGLCCCP1189452-5CP887679- 25proBNP (108 aa)BNP-32 (proBNP 77-108) BNP-32Physiologically active formNT-proBNP 1-76SecretionLV stretchWall tensionPre-proBNP (134 aa)Signal peptide (26 aa)pr
15、oBNPSerin protease(Corin?)Mair: Scand J Clin Lab Invest, 1999CP1189452-10CP887679- 26CP1189452-2097.5%percentile(pg/mL)3030-3940-4950-59 60Age groupsMalesFemalesCP887679- 27AHJ 149(4), April 2005CP1189452-21CP887679- 2838 4BNPconcentration(pg/mL)Diagnosisn=1391,076 138No CHFCP1189452-25n=97CHFLV dys
16、functionNo acute CHFn=14141 31CP887679- 29MedianBNP level(pg/mL)CP1189452-26BNP Levels in Normal Subjects and Inpatientswith Heart FailureNormalIIIIIIIVClassCP887679- 30CP1189452-27ED Probability of CHF RecordedP0.0001 from clinical judgment to combinedMcCullough PA et al: Circulation 106:416, 2002D
17、iagnostic accuracy (%)ClinicaljudgmentBNPCombined7072747678808274.081.281.5n=1,538CP887679- 31n=1,586; 50% CHF; 56% male;6417 yo; 41% COPD; 30% Hx CHFCP1189452-28 BNP(pg/mL)SensSpecPPVNPV 50976271951009076798915085838385AUC = 0.91CP887679- 32AJC 95, April 15, 2005Optimal cut-point Sens Spec PPV NPV
18、Accuracy(%) (%)(%)(%)(%) (%)Rule-in cutpointsAll pt (n=599)900908576948750 yr old4509395679995n=144 50 yr old9009180779285n=455Rule-out ptAll pt (n=599) 3009968629983CP1189452-30CP887679- 33McCullough PA et al for the BNP Multinational Study Investigators: J Am Coll Cardiol 41:278A, 2003Application
19、of BNP Testing in CHF“Grey Zone” BNPBNP (pg/mL)“Grey Zone” BNP100-500 pg/mL26.4% of all cases16.5%CHF7.9%No CHF0100200300400500600700800900 1,000 1,100 1,200 1,300CP1189452-31CP887679- 34CP1189452-32pg/mLCoronary pulmonale200-500Primary pulmonary300-500 hypertensionAcute pulmonary150-500 embolismCP8
20、87679- 35CP1189452-33Acute or chronic systolic or diastolic HFLV hypertrophyInflammatory cardiac diseasesSystemic arterial hypertension with LVHPulmonary hypertensionAcute or chronic renal failureAscitic liver cirrhosisEndocrine disorders (eg, hyper-aldosteronism, Cushings syndrome)CP887679- 36CP118
21、9452-34Well HF patientsAcute mitral regurgitationPulmonary edema 1 hour oldOther cases “up-stream” fromleft ventricleMitral stenosisAtrial myoxmaCP887679- 371.21.85.08.401234567891030 Days6 Months%P 0.0001P = 0.9Baseline BNP & Clinical Outcomes P 0.0001P = 0.9DeathMI3.85.24.15.301234567891030 Days6 Months%BNP 80N = 1356N = 320Morrow DA JACC 2004 CP887679- 38CP1173030-6*P250 ng/L250 n
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 目标设立与市场定位分析
- 创业企业品牌营销渠道创新重点基础知识点
- 创业企业品牌建设重点基础知识点
- 网络营销的渠道策略概述
- 安徽省皖南八校2024-2025学年高一下学期4月期中考试数学试题
- 邯郸市馆陶一中高二上学期第一次月考数学试卷
- 学校安全风险防控体系工作建设方案(3篇)
- 2025教师个人发展规划工作总结(3篇)
- 2023年湖北省人才发展集团有限公司社会招聘【10人】笔试参考题库附带答案详解
- 2025至2031年中国多功能商用门行业投资前景及策略咨询研究报告
- 软件验证报告模板参考(完整版)资料
- 杂质研究课件
- 输液港的植入和并发症处理课件
- 世界史知识点总结
- 公司IPQC巡检记录表
- 施工现场建筑垃圾处置专项方案
- 环形锻件的轧制过程的基本原理和工艺流程
- 妇幼保健院医疗保健服务转介工作制度和流程
- 监察机关执法工作规定学习测试
- 超细干粉灭火系统施工质量记录表格
- 2022职业病防治法宣传周PPT
评论
0/150
提交评论